Christopher Pieczonka, MD, director of clinical research, Crouse Health, discusses where the novel agent sabizabulin (VERU-111) would fit in the metastatic castration-resistant prostate cancer (mCRPC) paradigm if it succeeds in an ongoing phase 3 trial (NCT04844749). The study is exploring single-agent sabizabulin as a second-line treatment for patients with mCRPC.
In the video, Pieczonka says that if sabizabulin is established as a second-line option, it would then be explored in the upfront setting, most likely in combination regimens. Positive phase 1b/2 data for the novel oral cytoskeletal disruptor VERU-111 in mCRPC were presented during the 2021 ASCO Annual Meeting (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi: 10.1200/JCO.2021.39.15_suppl.5056).